Gilead Sciences to Acquire MiroBio

FOSTER CITY, Calif. & OXFORD, England--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405...

Click to view original post